Enspryng Injection, Solution
Product Images NDC 50242-005

Product Visual Gallery

This gallery contains 37 technical images submitted to the FDA as part of the official labeling for Enspryng (NDC 50242-005). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Enspryng 01)

A Kaplan-Meier survival curve chart depicting the proportion of patients relapse free over time (weeks) for two groups: Placebo (N=23) and ENSPRYNG (N=41). The chart shows ENSPRYNG maintained a higher relapse-free proportion (76.5%) at week 96 compared to placebo (41.1%). It includes risk reduction, hazard ratio, and censored data points. Patient numbers at risk for each time point are shown in a table below the graph.*

FDA Label Image

Figure 2 (Enspryng 02)

A Kaplan-Meier survival curve graph depicting proportion relapse-free over time in weeks for two groups: ENSPRYNG (solid line) and placebo (dashed line), each with 26 patients. The chart shows significantly higher relapse-free survival for ENSPRYNG at 96 weeks (91.1%) compared to placebo (56.8%). The graph includes censored data markers and a patient risk table below the x-axis.*

FDA Label Image

Image (Enspryng 03)

An instructional diagram showing four sequential steps or items, including a square-shaped item resembling a pad, a cotton ball or similar soft material, a square gauze, and an adhesive bandage, followed by a sharp disposal container with a slot on top and a label area. This likely illustrates steps related to subcutaneous injection care and sharps disposal.*

FDA Label Image

Figure A (Enspryng 04)

Illustration showing the labeled parts of a syringe intended for subcutaneous injection, with components including needle cap, barrel, expiration date, activation guards labeled as 'Do not touch,' and plunger.*

FDA Label Image

Figure B (Enspryng 05)

An instructional illustration showing a subcutaneous injection device with a needle shield extended and locked in place. The diagram highlights the needle shield feature for safe use, likely related to Enspryng (Satralizumab) injection administration.*

FDA Label Image

Figure C (Enspryng 06)

An instructional illustration showing how to check the expiration date and seal of a medication carton. It directs the user to check the expiration date on the back and verify that the carton is sealed with a lock icon indicating the sealed area.*

FDA Label Image

Figure D (Enspryng 07)

An instructional diagram showing an open flat box packaging, with an upward arrow indicating the opening direction of the box.*

FDA Label Image

Figure E (Enspryng 08)

An illustration showing the opening of a product carton with an arrow pointing to a hand holding a prefilled syringe. The syringe is being held with the thumb press area visible, indicating how to handle the injection device for subcutaneous use.*

FDA Label Image

Figure F (Enspryng 09)

Illustration showing a hand holding a syringe filled with liquid. It includes reminders to check the expiration date, inspect the liquid inside, and check the syringe for any damage before use. An eye icon emphasizes visual inspection.*

FDA Label Image

Figure G (Enspryng 10)

Illustration showing a clock-like circle with half shaded and an arrow indicating a clockwise rotation, accompanied by text "30 min" below. This likely represents a 30-minute time instruction or duration.*

FDA Label Image

Figure H (Enspryng 11)

An instructional illustration showing two hands being washed under running water with soap lather, emphasizing proper handwashing technique.*

FDA Label Image

Figure I (Enspryng 12)

An illustration showing recommended injection site areas on the human body for subcutaneous administration. Highlighted regions include the abdomen around the navel area and the front of the thighs. The diagram is labeled 'Injection site areas.'*

FDA Label Image

Figure J (Enspryng 13)

An instructional line drawing showing a hand using a cloth or wipe to clean or prep the skin, likely demonstrating a step in the preparation for a subcutaneous injection.*

FDA Label Image

Figure K (Enspryng 14)

An instructional illustration showing a person removing a cap from the needle of a syringe held in the other hand. The syringe appears designed for subcutaneous injection, consistent with Enspryng (satralizumab) injection use instructions.*

FDA Label Image

Figure L (Enspryng 15)

An instructional illustration showing a hand holding a syringe for subcutaneous injection into the skin. A smaller inset diagram shows acceptable injection angles at 45 and 90 degrees with "OK" noted, guiding proper injection technique.*

FDA Label Image

Figure M (Enspryng 16)

An instructional illustration showing how to operate a prefilled injection device. The left side depicts a hand pressing down the plunger, indicated by a downward arrow. The right side shows a finger pressing the top of the device, with lines indicating activation or engagement of the mechanism.*

FDA Label Image

Figure N (Enspryng 17)

Instructional illustration showing two steps for using an injection device. The first step depicts pulling the cap or cover straight up to remove it. The second step shows pressing the plunger or activation button on the injection device, with indications of activation marks around the plunger area.*

FDA Label Image

Figure O (Enspryng 18)

An instructional illustration showing the disposal of a syringe into a sharps disposal container, depicting safe injection waste handling.*

FDA Label Image

Image (Enspryng 19)

Enspryng (satralizumab-mwge) injection, 120 mg/mL, is shown on a label for a single-dose prefilled syringe intended for subcutaneous use. The label includes storage instructions, an attention note to pharmacists regarding the enclosed Medication Guide, and is marked for prescription use by Genentech, Inc.*

FDA Label Image

Image (Enspryng 20)

An instructional illustration showing parts of an Enspryng (Satralizumab) prefilled syringe for subcutaneous injection. The image labels the removed cap, green needle shield, and green plunger on the syringe body.*

FDA Label Image

Image (Enspryng 21)

An instructional illustration showing four items related to medication administration: a sealed packet, a textured wipe or gauze pad, a cotton ball, an adhesive bandage, and a prescription pill bottle with a blank label.*

FDA Label Image

Image (Enspryng 22)

An instructional illustration showing a hand removing a prefilled syringe from a plastic tray next to an open carton box, indicating safe handling or preparation of the injection solution.*

FDA Label Image

Image (Enspryng 23)

An instructional illustration showing a hand holding an injection pen device. Adjacent icons and text remind users to check the expiration date, inspect the medicine, and look for any damage before use.*

FDA Label Image

Image (Enspryng 24)

An illustration showing a clock face with half of it shaded in blue and a curved arrow indicating clockwise rotation. Below the clock is text stating "30 minutes," likely representing a time duration.*

FDA Label Image

Image (Enspryng 25)

An illustration showing the recommended subcutaneous injection sites for Enspryng (Satralizumab). The diagram highlights the stomach area and the front of the thighs as suitable injection locations on a simplified human figure.*

FDA Label Image

Image (Enspryng 26)

An instructional illustration showing two steps: washing hands under running water, followed by wiping an area of skin with a cloth or swab, likely indicating preparation for a subcutaneous injection.*

FDA Label Image

Image (Enspryng 27)

An instructional illustration showing a hand removing the cap from an injection device with a green needle shield inside. The image includes a caution not to touch the green needle shield, emphasizing safety handling of the needle during preparation for subcutaneous injection.*

FDA Label Image

Image (Enspryng 28)

An instructional illustration showing how to properly hold and use an injectable pen device. The main image depicts a hand gripping the pen vertically with the needle facing downward, with a dotted line indicating the injection direction. An inset on the top left contrasts correct and incorrect pen angles for injection, marking the vertical position as correct and the angled position as incorrect.*

FDA Label Image

Image (Enspryng 29)

Instructional illustration showing how to use the Enspryng subcutaneous injection. It depicts holding the injection device in place at the start, watching the green plunger move, and continuing until hearing two clicks, indicating the end of the injection process.*

FDA Label Image

Image (Enspryng 30)

An instructional illustration showing a hand holding a subcutaneous injection device aimed at skin. A visual guide depicts aligning the window on the device with the injection site as indicated by an eye icon, with a small inset showing an incorrect orientation marked by a red X.*

FDA Label Image

Image (Enspryng 31)

Illustration showing a hand holding an injection device upright with an arrow pointing upward, positioned above a surface, likely demonstrating the preparation or administration step for a subcutaneous injection.*

FDA Label Image

Image (Enspryng 32)

An instructional illustration showing a medication vial with a cap being removed or manipulated, alongside a single-use injection device with a removable cap, indicating preparation steps for subcutaneous injection delivery.*

FDA Label Image

Image (Enspryng 33)

An illustration showing common injection site preparation materials including a square alcohol pad, a cotton ball, and a rectangular adhesive bandage. These are typically used for subcutaneous injection site care.*

FDA Label Image

Image (Enspryng 34)

Enspryng 120 mg/mL injection solution in a single-use vial. The vial is clear with a white label displaying black text. It is a subcutaneous human prescription drug labeled by Genentech, Inc. The vial contains 120 mg/mL Satralizumab.*

FDA Label Image

Principal Display Panel (120 mg/mL Syringe Carton)

Label for Enspryng (satralizumab-mwge) Injection, 120 mg/mL, a single-dose prefilled syringe for subcutaneous use. The label includes storage instructions to refrigerate at 2°C to 8°C (36°F to 46°F) in the original carton, avoid freezing and shaking, and a note for pharmacists about providing the medication guide. Manufactured by Genentech, Inc.*

FDA Label Image

Principal Display Panel (120 mg/mL Autoinjector Carton)

Label for Enspryng (satralizumab-mwge) Injection 120 mg/mL, a subcutaneous injection solution. The label indicates it is a single-dose autoinjector with instructions to discard after use. The product is labeled by Genentech, Inc. and includes a reminder for pharmacists to provide the enclosed medication guide to patients.*

FDA Label Image

Principal Display Panel (180 mg/1.5 mL Autoinjector Carton)

Label for Enspryng (satralizumab-mwge) Injection, 180 mg/1.5 mL solution for subcutaneous use. The label notes this is a single-dose autoinjector and instructs to discard after use. The manufacturer is Genentech, Inc. The NDC is 50242-005-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.